Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
Sign Up to like & getrecommendations! Published in 2022 at "Pulmonary Circulation"
DOI: 10.1002/pul2.12028
Abstract: Abstract Pulmonary hypertension (PH) is a highly morbid condition. PH due to left heart disease (PH‐LHD) has no specific therapies and pulmonary arterial hypertension (PAH) has substantial residual risk despite several approved therapies. Multiple lines… read more here.
Keywords: pulmonary hypertension; inhibitors glp1; sglt2 inhibitors; glp1 agonists ... See more keywords
Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice
Sign Up to like & getrecommendations! Published in 2020 at "Nature Reviews Nephrology"
DOI: 10.1038/s41581-020-0312-7
Abstract: Clinical trials of sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists have shown beneficial effects of these agents on kidney outcomes in patients with type 2 diabetes mellitus. Two new cohort… read more here.
Keywords: sglt2 inhibitors; clinical practice; renal outcomes; outcomes sglt2 ... See more keywords